Quickly verify claims by accessing the underlying experimental data and figures.
Press Enter β΅ to solve
Fuel Your Discoveries
"Two possibilities exist: either we are alone in the Universe or we are not. Both are equally terrifying."
- Arthur C. Clarke
Quick Explanation
Copied
DNMT1 as a TNBC hub (review-level evidence)
The paper argues that DNMT1 is overexpressed in TNBC/basal-like breast cancer and contributes to ER silencing, EMT, autophagy, and cancer stem cell maintenance, and it surveys DNMT1-targeting epigenetic therapies (HMAs like azacitidine/decitabine and related DNMTi strategies, plus experimental DNMT1 inhibitors) with an emphasis on possible combination concepts.
Evidence base:
predominately mechanistic and correlative literature; clinical outcomes in TNBC with HMAs remain limited/variable.
Paper Review (Science-skeptical, evidence-based): DNMT1 in Triple-Negative Breast Cancer
Review target: DOI 10.1016/j.semcancer.2020.05.010 (journal pre-proof content).
Quick read map (what the paper claims)
TNBC/ basal-like association: DNMT1 transcript expression is higher in TNBC/basal-like vs normal breast in TCGA-derived analyses (GEPIA2), and the review also summarizes multiple cohort/IHC associations with grade, receptor status, and prognosis.
Mechanistic βaxesβ: DNMT1 is positioned as influencing ER silencing, EMT (emphasizing E-cadherin/CDH1), autophagy (including circ-DNMT1 claims), and cancer stem cell maintenance.
Therapeutic overview: The review contrasts nucleoside HMAs (azacitidine/decitabine) and related strategies (including guadecitabine) and also discusses experimental DNMT1 inhibitors; it highlights that clinical benefit in TNBC has been limited/variable and motivates combination ideas (e.g., epigenetic priming with ICB concepts).
Figure-grade visuals from the reviewβs extracted numeric claims
Note: The review is not a single original experimental study. The numbers below are taken only from the provided full-text content and extracted dataset summaries.
Source: reviewβs SNP case-control summary of rs2288349 and rs16999593 with ORs 5.27 and 4.13.
Source: reviewβs Figure 1 description of TCGA counts used in DNMT1 expression across subtypes.
Source: reviewβs summary of a phase II trial of entinostat + azacitidine in TNBC and reported primary endpoint not met; and a small phase I context in advanced breast cancer (review-reported).
Mechanism diagram (conceptual, review-assembled)
This is a schematic map of pathways explicitly discussed in the review text. It does not represent new measurements.
Source: mechanistic and pathway sections summarized throughout the review (ER silencing, EMT/CDH1, autophagy/circ-DNMT1, CSC maintenance, CAF microenvironment links, and inhibitor classes).
Critical appraisal (skeptical, mechanistic, and translation-aware)
What seems well-supported (within the limits of a review)
Biological plausibility: DNMT1 is positioned as a maintenance methyltransferase with a rationale for epigenetic gene repression; the reviewβs emphasis on maintenance methylation and promoter CpG methylation is consistent with core epigenetics literature (though this specific review mostly synthesizes rather than re-tests).
Correlative directionality: The review reports a consistent direction for DNMT1 being higher in TNBC/basal-like, plus association with aggressive features and worse outcomes across multiple studies (IHC cohorts and TCGA/GEPIA2 summaries).
Multi-step mechanistic narrative: The review connects DNMT1 to several hallmarks (ER silencing/therapy resistance, EMT invasion programs, autophagy and CSC maintenance), which is coherent as an epigenetic βcontrol node,β even though causality can be gene- and context-dependent.
Where the evidence is weaker or could mislead (review-level blind spots)
Correlation β causation in many sections: TNBC DNMT1 upregulation and associations with prognosis can be confounded by general cell-cycle state, tumor subtype biology, and stromal compositionβespecially when expression is measured in bulk cohorts. (This is a general methodological caution; the review compiles such studies rather than reanalyzing them uniformly.)
Mechanistic overreach risk: The review describes DNMT1 recruitment to promoters and downstream gene regulation (e.g., EMT and ER silencing axes). Without unified, systematically tested causal chains in the same TNBC patient-derived contexts, individual pathway claims may not generalize across TNBC heterogeneity.
Therapeutic translation is non-trivial: HMAs and DNMT inhibitors have dose/schedule issues, off-target biology, and complex immune effects; clinical efficacy in TNBC has been limited/controversial (including a reported phase II lack of partial responses in 13 TNBC patients in one combination study).
Biomarker specificity uncertainty: The review discusses that DNMT expression may relate to response to decitabine in TNBC PDX/organoid contexts, but this does not guarantee that DNMT1 alone will predict response in all patient cohorts and treatment regimens.
What would most likely disprove/reshape the DNMT1-as-TNBC-driver claim?
Not overexpressed / not causal: Consistent across large TNBC patient datasets, DNMT1 would not be enriched over normal or would not correlate with aggressive phenotypes, and DNMT1 perturbation would not reverse key methylation/phenotype readouts in relevant TNBC models.
Pathway substitution: If the same phenotypic transitions (ER re-expression, EMT marker de-repression, autophagy/CSC changes) occur without DNMT1-dependent promoter methylation changes, then DNMT1 would be a marker or downstream correlating factor rather than a necessary driver in TNBC.
Therapy mismatch: If DNMT-targeting strategies do not show repeatable molecular engagement in TNBC (i.e., no re-expression of predicted gene sets or methylation signature reversal) and show no clinical benefit in properly powered trials, the therapeutic positioning would need major revision.
Author review links (bespoke next step)
The provided full-text XML shows the corresponding authorβs full name clearly as Keng Kah Wong, but other author-name fragments are ambiguous in the extracted header. Below are the links that can be formed unambiguously from the visible metadata.
Feedback:
Updated: March 25, 2026
BGPT Paper Review
Study Novelty
60%
As a narrative review, novelty comes mainly from synthesis framing around DNMT1 as a TNBC target and from grouping therapeutic/biological axes; the underlying mechanisms are largely established across prior studies rather than introducing new primary findings.
Scientific Quality
70%
Moderate-to-good scientific quality as a synthesis: it provides a coherent multi-axis mechanistic narrative (ER silencing, EMT, autophagy, CSC, microenvironment) and includes at least some numerical summaries from cohort/TCGA and clinical trial contexts; however, as a review, reproducibility is inherently limited because methods/data generation are not provided uniformly and much is correlational/preclinical.
Study Generality
70%
The target (DNMT1) and biological themes (epigenetic maintenance methylation driving gene repression, EMT, CSC, and therapy resistance) are generalizable across cancers, but the emphasis is TNBC-specific.
Study Usefulness
70%
Useful as a map of where DNMT1 sits in TNBC biology and for identifying which experimental/clinical trial angles exist; however, because itβs not a systematic review and does not provide original datasets, it is less directly actionable for hypothesis testing without extracting primary studies.
Study Reproducibility
40%
As a narrative review, there is no unified experimental method section with primary data generation; while it cites TCGA/GEPIA2 and trial IDs, exact re-analysis pipelines and all raw numbers are not packaged for independent reproduction from the review alone.
Explanatory Depth
70%
The review provides relatively deep mechanistic scaffolding (ER silencing β EMT β autophagy β CSC; and microenvironment links) but explanatory power is limited by heterogeneity of underlying studies and by gaps where promoter methylation causality is not uniformly established in patient contexts.
Plots review-extracted DNMT1 TNBC-related odds ratios and TCGA subtype sample counts, and visualizes a minimal clinical response signal, using only the numbers explicitly stated in the manuscript text.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
If DNMT1 inhibition primarily produces phenotypes via broad DNA damage, general cell stress, or off-target demethylation rather than DNMT1-linked locus-specific promoter methylation, then DNMT1 would be a non-specific upstream correlate and the ER/EMT/DDX-specific mechanistic model would weaken.
If TNBC heterogeneity leads DNMT1βs dominant contribution to vary across subtypes (e.g., claudin-low vs other basal-like programs), then a single DNMT1-focused driver model would be insufficient without subtype-resolved causal mapping.
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Keep Exploring
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Key Insight
